NCCN Guidelines Designate Decipher Prostate as "Recommended" for Men with Adverse Pathology after Radical Prostatectomy
The first and only genomic test to achieve "Recommended" status for the management of prostate cancer patients
SAN DIEGO, March 24, 2020 -- (Healthcare Sales & Marketing Network) -- Decipher Biosciences, a commercial-stage precision oncology ... Diagnostics, Urology, Oncology Decipher Biosciences, Decipher Prostate RP, prostate cancer, NCCN
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Marketing | Pathology | Pharmaceuticals | Prostate Cancer | Prostatectomy | Urology & Nephrology